Article
Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.
Arthritis & rheumatology (Hoboken, N.J.) - 1 Apr 2017
Cui Jing, Diogo Dorothee, Stahl Eli A, Canhao Helena, Mariette Xavier, Greenberg Jeffrey D, Okada Yukinori, Pappas Dimitrios A, Fulton Robert S, Tak Paul P, Nurmohamed Michael T, Lee Annette, Larson David E, Kurreeman Fina, Deluca Tracie L, O'Laughlin Michelle, Fronick Catrina C, Fulton Lucinda L, Mardis Elaine R, van der Horst-Bruinsma Irene E, Wolbink Gert-Jan, Gregersen Peter K, Kremer Joel M, Crusius J Bart A, de Vries Niek, Huizinga Tom W J, Fonseca João Eurico, Miceli-Richard Corinne, Karlson Elizabeth W, Coenen Marieke J H, Barton Anne, Plenge Robert M, Raychaudhuri Soumya
Abstract excerpt
OBJECTIVE: In many rheumatoid arthritis (RA) patients, disease is controlled with anti-tumor necrosis factor (anti-TNF) biologic therapies. However, in a significant number of patients, the disease fails to respond to anti-TNF therapy. We undertook the present study to examine the hypothesis that rare and low-frequency genetic variants might influence response to anti-TNF treatment. METHODS: We sequenced the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.